Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies
Katrine Melvold(Oslo University Hospital), Sigrid S. Skånland(Oslo University Hospital)
Cited by 16
Related Papers
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
|Blood|2021|70
Phosphoinositide‐Regulated Retrograde Transport of Ricin: Crosstalk Between hVps34 and Sorting Nexins
|Traffic|2006|60
PI3K Inhibitors in Hematology: When One Door Closes…
|Clinical Cancer Research|2024|23
A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine
|Cell Death Discovery|2023|17
Standardized assays to monitor drug sensitivity in hematologic cancers
|Cell Death Discovery|2023|17